All In Biotech

Drug Trial Radar · NCT02194400

Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus

A Double-Blind, Placebo-Controlled Dose Escalation Study of the Administration of Multiple Intravenous Doses of RSLV-132 in Subjects With Systemic Lupus Erythematosus

Last checked: Nov 20, 2026Latest source record: Dec 9, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Jul 2014

Primary completion

Nov 2015

Study completion Nov 2015

Sponsor

Lead sponsor
Resolve TherapeuticsIndustry
Sponsor type
Industry
First posted
Jul 18, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A one month multi-dose study will evaluate the safety and tolerability of 3 intravenous infusions of RSLV-132 in subjects with inactive to mild SLE.

Conditions

  • Systemic Lupus Erythematosus

Interventions

  • RSLV-132Biological

    0.3 - 10.0 mg/kg RSLV-132 weekly for 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0Time frame: 30 days

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Research of West Florida

    Clearwater, Florida

  • West Michigan Rheumatology

    Grand Rapids, Michigan

  • Altoona Center for Clinical Research

    Duncansville, Pennsylvania

  • Metroplex Clinical Research

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.